Google
BMEA 株価分析 — Biomea Fusion Inc (Healthcare >> Biotechnology)
BMEA に関するよくある質問
BMEAのPER（株価収益率）は？
Biomea Fusion Inc（BMEA）は現在PER 19.28倍で取引されています。
BMEAのROE（自己資本利益率）は？
Biomea Fusion IncのROEは-240.13%です。
BMEAの配当利回りは？
Biomea Fusion Incの配当利回りは0.00%です。
BMEAの品質スコア（Quality Score）は？
当社のAIはBMEAの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BMEAは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BMEAはどのセクターに属しますか？
Biomea Fusion IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
BMEA AI Analysis Summary
Our AI summary for BMEA: Biomea Fusion Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 19.28, ROE of -240.13%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.26
Price
0.03
(2.44%)
Day Change
|
|
|---|
BMEA, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.26 |
| PBV / Sector |
4.75 / 44,105.10
|
| Earning Per Share | -0.64 |
| PE / Sector |
19.28 / 19.37
|
| PEG or PE/Growth / Sector |
-1.82 / 1.06
|
| Average 1M Daily Value |
0.74 M
GREAT
|
| Average 1W Daily Value |
0.65 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:43 |
| Symbol | BMEA |
| Name | BIOMEA FUSION INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 72.30 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 88.93 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1599 Industrial Road, San Carlos, CA, United States, 94070
Phone: 650 980 9099
Website: https://biomeafusion.com
Sector: Healthcare >> Biotechnology
Description: Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
